Bachner P, Hamlin W
Department of Pathology and Laboratory Medicine, United Hospital Medical Center, Port Chester, New York.
Clin Lab Med. 1993 Sep;13(3):739-52; discussion 737-8.
In this first part of a two-part article, we have summarized some of the pertinent features of CLIA 1988 with review of the complexity model, waived testing, personnel standards, proficiency testing and quality control requirements, and patient test management. In addition to a survey of other Federal regulations applicable to clinical laboratories, we have briefly reviewed events subsequent to the publication of the Final Rule in February of 1992, specifically the recommendations of CLIAC and the Technical Corrections published on January 19, 1993. The second part of this paper will discuss sanctions and enforcement; how laboratory inspections are likely to be performed, accreditation of private organizations, state exemptions, cytology and other specialty regulations, and the evolving interaction between CLIAC, FDA, CDC, DHHS, and the regulated laboratory community.
在这篇分两部分的文章的第一部分中,我们总结了1988年《临床实验室改进修正案》的一些相关特征,回顾了复杂性模型、简易检测、人员标准、能力验证和质量控制要求以及患者检测管理。除了对适用于临床实验室的其他联邦法规进行调查外,我们还简要回顾了1992年2月最终规则发布后的相关事件,特别是临床实验室改进咨询委员会(CLIAC)的建议以及1993年1月19日发布的技术修正。本文的第二部分将讨论制裁与执法;实验室检查可能如何进行、私人组织的认可、州豁免、细胞学及其他专业法规,以及CLIAC、美国食品药品监督管理局(FDA)、美国疾病控制与预防中心(CDC)、美国卫生与公众服务部(DHHS)与受监管的实验室群体之间不断演变的互动。